Home › Meningioma › NCT06377371
Feasibility of Intraoperative Tracing of Meningioma Using [Cu64]DOTATATE
RecruitingPhase 4
A Pilot Study to Evaluate Feasibility of Intraoperative Tracing of Meningioma Using [Cu64]DOTATATE
Who can join
Ages 18 to 99 · All sexes
Full eligibility criteria
Inclusion Criteria: * High suspicion of meningioma necessitating surgical resection based on conventional MRI criteria, or diagnosis of meningioma based on pathology reports from prior resection with radiographic findings of suspected recurrent or residual tumor necessitating repeat surgery. Exclusion Criteria: * Pregnant or breastfeeding * Patients undergoing endoscopic endonasal resection, eyebrow incision surgery, or any surgical procedure in which the neoprobe cannot be employed * Patients with hypersensitivity to somatostatin analogs * Patients with contraindications to conventional MRI * Patients with prior history of cranial radiation therapy * Patients currently enrolled in other therapeutic clinical trials related to meningioma will be excluded
About the study
The study team hypothesizes that it is feasible to intraoperatively detect tumor following \[CU64\]DOTATATE injection using the gamma probe device.
What is being tested
- Brain Imaging with [Cu64]DOTATATE (diagnostic test)
- Radio-guided Surgery With Neoprobe Utilization (procedure)
Sponsor: Weill Medical College of Cornell University · Participants: 20 · Started: Sep 11, 2024
Contact the study team
- Jana Ivanidze, MD/PhD · Phone: 212-746-4587
- Alexis Watson · Phone: 646-962-2347
Official record on ClinicalTrials.gov — NCT06377371
Locations in the U.S.
| New York | New York-Presbyterian/Weill Cornell Medical Center, New York |
Conditions
From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.